Understanding Control and Mechanisms of Shoulder Instability in FSHD

May 4, 2022 updated by: University of Liverpool

Understanding Control and Mechanisms of Shoulder Instability in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)

The aim of this study is to identify factors for shoulder instability in people with Facioscapulohumeral dystrophy (FSHD). FSHD is a non-life limiting condition with symptoms presenting in the second decade of life (Evangelista et al., 2016). Between 2500 to 3000 people are diagnosed with FSHD in the UK and it is the third most common dystrophy. The overall prevalence is 1: 20,000 and on average 52 people are newly diagnosed with FSHD each year (Emery, 1991; Padberg et al., 1995; UK, 2020) As the disease progresses, patients lose the ability to adequately control muscles around the shoulder girdle, possibly contributing to the development of shoulder instability i.e. partial or complete dislocation of the shoulder joint (Bergsma, Cup, Geurts, & De Groot, 2015; Bergsma, Cup, Janssen, Geurts, & de Groot, 2017; Mul et al., 2016). Loss of control around the shoulder is also thought to contribute to pain and a reduced capacity to perform tasks above shoulder height. Additionally, the development of fatigue and chronic pain further limit patient's abilities and engagement with rehabilitation.

If we better understand the mechanisms associated with instability, we can better target physiotherapy interventions to improve rehabilitation. If we identify specific patterns of activity associated with instability, these could be addressed through personalised and improved exercise prescription and rehabilitation. Additionally, we may identify causes of instability for which physiotherapy or exercise programmes may not be appropriate, therefore ensuring patients are referred to the correct service in a timely manner, improving patient outcomes and allocating resources more appropriately.

Study Overview

Detailed Description

Shoulder instability in Facioscapulohumeral dystrophy (FSHD) is a significant problem, with over 80% of patients reporting that it affects their ability to perform activities of daily living (Faux-Nightingale , 2021). The underlying mechanisms of shoulder instability in FSHD are not well understood. It is thought that instability at the shoulder subsequently contributes to the development of shoulder pain and progressive loss of function, particularly during tasks performed above head height. Despite a large proportion of patients reporting shoulder instability that affects function, only 50% report engaging in some form of upper limb rehabilitation (Faux-Nightingale , 2021).

Both surgical and nonsurgical interventions are based on a current understanding of the associated mechanisms that may include muscle wasting, weakness, changes to the structure of the muscle tissue or inappropriate muscle coordination (Bergsma et al., 2014). As there is no cure for FSHD, rehabilitation is fundamental in the management of the condition. Overall, rehabilitation strategies are aimed at maintaining existing levels of function, avoiding complications associated with progression of the disease and targeting mechanisms associated with the development of instability. e.g. exercises to improve co-ordination of the shoulder muscles if the source of instability is dysfunctional muscle control.

Rehabilitation in patients with FSHD is complex and it is therefore important that rehabilitation is appropriately targeted. There is limited evidence to support the effectiveness of existing rehabilitation strategies in FSHD. In order for rehabilitation to be appropriately allocated disease mechanisms should be understood. Existing mechanisms of shoulder instability in FSHD are not well understood and may explain why more than 50% of patients are not engaging in any form of upper limb rehabilitation.

Shoulder stability results from complex mechanisms comprising of finely balanced forces in ligaments, muscles and joint surfaces (Ameln, Chadwick, Blana, & Murgia, 2019). Currently, we are unable to capture this complexity to quantify instability during dynamic upper limb tasks performed during clinical assessment and rehabilitation (Marchi, Blana, & Chadwick, 2014). Biomechanical or mathematical modelling of this complex structure can help to understand the mechanisms associated with instability and predict outcomes for surgical and non-surgical interventions (Arnold, Liu, Ounpuu, Swartz, & Delp, 2006; Delp et al., 2007; Laracca, Stewart, Postans, & Roberts, 2014). Loading on internal structures that cannot be measured can also be estimated by this approach.

This project is therefore a fundamental step, in the development of biomechanical models which can ultimately be used to further our understanding of the shoulder, specifically behaviour of the articulating bony surfaces and muscle forces. In this application we hope to identify mechanisms for shoulder instability which may help better inform rehabilitation and surgical decision making in the management of FSHD.

Study Type

Observational

Enrollment (Anticipated)

14

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Gobowen
      • Oswestry, Gobowen, United Kingdom, SY10 7AG
        • Recruiting
        • Robert Jones & Agnes Hunt Orthopaedic Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

This study will consist of people aged 18 years of age and older. The two groups will include people with (people affected by FSHD) and without FSHD (age matched controls).

Description

People affected by FSHD

Inclusion Criteria:

Stratified groups

  • Able to lift arms above shoulder height (n=3)
  • Unable to lift arms above shoulder height (n=2)
  • Post Scapulothoracic shoulder arthrodesis (n=2)
  • Diagnosed with FSHD
  • Aged 18 years and older

Exclusion Criteria:

  • Recent trauma to the shoulder within the last 3 months on the arm being assessed that has not resolved
  • Recent surgery to the thorax or upper limb in the last 6 months
  • Previous history of fracture to the shoulder joint being assessed
  • Co-existing neurological pathologies or additional musculoskeletal injuries to the upper limb being assessed

Age Matched Controls

Inclusion Criteria

- People aged 18 years and older

Exclusion Criteria:

  • Any previous presentation to a health care professional with a diagnosis of shoulder instability
  • Previous shoulder injury within the last 3 months on the arm being assessed that has not resolved
  • Any co-existing neurological pathologies or deficits
  • Any previous surgical intervention on the arm being assessed
  • Currently undergoing or awaiting medical management, diagnostic investigations or rehabilitation on the arm being assessed

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
People affected by FSHD
Participants with a diagnosis of FSHD. 3D movement analysis session including surface electromyography and Ultrasound.
Single measurement session of 3D movement analysis with surface electromyography for upper limb movements and ultrasound measurements of upper muscles
Age matched control group
Participants without a diagnosis of FSHD. 3D movement analysis session including surface electromyography and Ultrasound
Single measurement session of 3D movement analysis with surface electromyography for upper limb movements and ultrasound measurements of upper muscles

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Kinematic features of movement: joint angles (degrees)
Time Frame: Day 1
Range of movement values and associated derivatives will be reported for the associated movement tasks.
Day 1
Kinematic features of movement: displacement (mm)
Time Frame: Day 1
Displacement values and associated derivatives will be reported for associated movement tasks.
Day 1
Kinetic variables related to the movement tasks: Force (Nm)
Time Frame: Day 1
Force values for the strength testing, joint contact and muscle force values will be reported for associated movement tasks.
Day 1
Muscle activity patterns related to the movement tasks: Surface electromyography (mv)
Time Frame: Day 1
Muscle activity patterns related to the movement tasks will be reported for associated movement tasks.
Day 1
Ultrasound imaging: Muscle architecture parameters (mm)
Time Frame: Day 1
Muscle architecture parameters where possible (Muscle thickness)
Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 25, 2022

Primary Completion (Anticipated)

February 27, 2023

Study Completion (Anticipated)

February 27, 2023

Study Registration Dates

First Submitted

January 27, 2022

First Submitted That Met QC Criteria

February 14, 2022

First Posted (Actual)

February 15, 2022

Study Record Updates

Last Update Posted (Actual)

May 5, 2022

Last Update Submitted That Met QC Criteria

May 4, 2022

Last Verified

February 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

The anonymised final trial dataset and anonymised 3D movement data files will be stored on the University of Liverpool data repository. The anonymised dataset associated with the University of Liverpool data repository will be assigned a Digital object identifier and will be openly available.

IPD Sharing Supporting Information Type

  • Study Protocol

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neuromuscular Diseases

Clinical Trials on 3D movement analysis with surface electromyography and ultrasound

3
Subscribe